Stock Yards Bank & Trust Co. Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Stock Yards Bank & Trust Co. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.4% during the second quarter, HoldingsChannel.com reports. The fund owned 2,541 shares of the medical research company’s stock after selling 428 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Thermo Fisher Scientific were worth $1,030,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Nuveen LLC purchased a new position in Thermo Fisher Scientific in the 1st quarter worth approximately $532,360,000. Sarasin & Partners LLP acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at $187,134,000. EdgePoint Investment Group Inc. purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth $172,139,000. Cohen Investment Advisors LLC lifted its holdings in Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company’s stock worth $167,271,000 after buying an additional 331,180 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after buying an additional 329,974 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Up 3.6%

NYSE:TMO opened at $543.88 on Friday. The company has a market capitalization of $205.37 billion, a price-to-earnings ratio of 31.46, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The stock has a 50-day simple moving average of $482.58 and a 200 day simple moving average of $447.27. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TMO shares. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating for the company. Finally, Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $585.37.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.